Levosimendan
Catalog No.S2446
Molecular Weight(MW): 280.28
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
Biological Activity
| Description | Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC). Levosimendan at 3 μM decreases the value of Ca50 from 2.73μM to 1.19 μM. levosimendan exhibits its calcium sensitizing effect through calcium-dependent binding to the N-terminal domain of cTnC. [1] Levosimendan significantly hyperpolarizes resting potential of rat mesenteric arterial myocytes with an EC50 of 2.9 μM and maximal effect (19.5 mV) at 10 μM, probably through activation of a glibenclamide-sensitive K+ channel. [2] Levosimendan has inotropic and lusitropic actions in failing human myocardium, with average maximum increase in twitch tension of 47% at a levosimendan concentration of 0.8 μM. [3] Levosimendan causes rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure. [4] |
|
| In vivo | Levosimendan at low concentrations (0.03 to 0.1 μM) acts preferably as a Ca2+ sensitizer, whereas at higher concentrations (0.1 to 0.3 μmol/L) its action as a phosphodiesterase inhibitor contributes to the positive inotropic effect. [5] |
Protocol
| Animal Research:[5] |
+ Expand
|
|---|
Solubility (25°C)
| In vitro | DMSO | 56 mg/mL (199.8 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble | |
| In vivo | Add solvents individually and in order: 30% propylene glycol, 5% Tween 80, 65% D5W |
30 mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 280.28 |
|---|---|
| Formula | C14H12N6O |
| CAS No. | 141505-33-1 |
| Storage | powder |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03022877 | Not yet recruiting | Myocardial Infarction|Outcome | RWTH Aachen University | June 2017 | -- |
| NCT01720030 | Active, not recruiting | Acute Kidney Injury | VieCuri Medical Centre|Orion Corporation, Orion Pharma | September 2016 | Phase 2|Phase 3 |
| NCT02640846 | Recruiting | Septic Shock|Cardiomyopathy | Sahlgrenska University Hospital, Sweden | December 2015 | Phase 4 |
| NCT02531724 | Recruiting | Acute Kidney Injury|Renal Insufficiency, Acute | Sahlgrenska University Hospital, Sweden | September 2015 | Phase 4 |
| NCT02232399 | Recruiting | Congenital Heart Defects | Göteborg University|Helsinki University Central Hospital | October 2014 | Phase 2 |
| NCT02025621 | Completed | Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome | Tenax Therapeutics, Inc. | July 2014 | Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
